QQQ   297.68 (+1.48%)
AAPL   146.86 (+2.01%)
MSFT   249.28 (+0.52%)
META   152.51 (+3.54%)
GOOGL   99.77 (+2.31%)
AMZN   102.87 (+3.68%)
TSLA   179.48 (+11.99%)
NVDA   204.85 (+3.45%)
NIO   12.85 (+5.59%)
BABA   118.93 (-1.36%)
AMD   76.28 (+1.49%)
T   19.98 (-0.10%)
MU   64.12 (+2.10%)
F   13.33 (+3.17%)
CGC   2.95 (+6.88%)
GE   83.56 (+2.98%)
DIS   110.20 (+0.46%)
AMC   5.53 (+4.73%)
PFE   44.08 (-0.38%)
PYPL   82.14 (+1.65%)
NFLX   362.99 (-0.52%)
QQQ   297.68 (+1.48%)
AAPL   146.86 (+2.01%)
MSFT   249.28 (+0.52%)
META   152.51 (+3.54%)
GOOGL   99.77 (+2.31%)
AMZN   102.87 (+3.68%)
TSLA   179.48 (+11.99%)
NVDA   204.85 (+3.45%)
NIO   12.85 (+5.59%)
BABA   118.93 (-1.36%)
AMD   76.28 (+1.49%)
T   19.98 (-0.10%)
MU   64.12 (+2.10%)
F   13.33 (+3.17%)
CGC   2.95 (+6.88%)
GE   83.56 (+2.98%)
DIS   110.20 (+0.46%)
AMC   5.53 (+4.73%)
PFE   44.08 (-0.38%)
PYPL   82.14 (+1.65%)
NFLX   362.99 (-0.52%)
QQQ   297.68 (+1.48%)
AAPL   146.86 (+2.01%)
MSFT   249.28 (+0.52%)
META   152.51 (+3.54%)
GOOGL   99.77 (+2.31%)
AMZN   102.87 (+3.68%)
TSLA   179.48 (+11.99%)
NVDA   204.85 (+3.45%)
NIO   12.85 (+5.59%)
BABA   118.93 (-1.36%)
AMD   76.28 (+1.49%)
T   19.98 (-0.10%)
MU   64.12 (+2.10%)
F   13.33 (+3.17%)
CGC   2.95 (+6.88%)
GE   83.56 (+2.98%)
DIS   110.20 (+0.46%)
AMC   5.53 (+4.73%)
PFE   44.08 (-0.38%)
PYPL   82.14 (+1.65%)
NFLX   362.99 (-0.52%)
QQQ   297.68 (+1.48%)
AAPL   146.86 (+2.01%)
MSFT   249.28 (+0.52%)
META   152.51 (+3.54%)
GOOGL   99.77 (+2.31%)
AMZN   102.87 (+3.68%)
TSLA   179.48 (+11.99%)
NVDA   204.85 (+3.45%)
NIO   12.85 (+5.59%)
BABA   118.93 (-1.36%)
AMD   76.28 (+1.49%)
T   19.98 (-0.10%)
MU   64.12 (+2.10%)
F   13.33 (+3.17%)
CGC   2.95 (+6.88%)
GE   83.56 (+2.98%)
DIS   110.20 (+0.46%)
AMC   5.53 (+4.73%)
PFE   44.08 (-0.38%)
PYPL   82.14 (+1.65%)
NFLX   362.99 (-0.52%)
NASDAQ:RVNC

Revance Therapeutics - RVNC Stock Forecast, Price & News

$33.51
-0.37 (-1.09%)
(As of 01/27/2023 03:35 PM ET)
Add
Compare
Today's Range
$32.88
$33.98
50-Day Range
$18.32
$33.88
52-Week Range
$11.27
$34.55
Volume
533,438 shs
Average Volume
2.32 million shs
Market Capitalization
$2.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.30

Revance Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
17.0% Upside
$39.60 Price Target
Short Interest
Bearish
16.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.55mentions of Revance Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$131,519 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.32) to ($3.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

711th out of 1,055 stocks

Pharmaceutical Preparations Industry

358th out of 519 stocks


RVNC stock logo

About Revance Therapeutics (NASDAQ:RVNC) Stock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Stock News Headlines

Revance Therapeutics (NASDAQ:RVNC) Price Target Raised to $26.00
Revance Therapeutics (NASDAQ:RVNC) PT Raised to $26.00
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
What 4 Analyst Ratings Have To Say About Revance Therapeutics
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Nanostics Announces New Member of Board of Directors
What 8 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics's Earnings: A Preview
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVNC
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.60
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+14.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-281,310,000.00
Net Margins
-251.92%
Pretax Margin
-251.27%

Debt

Sales & Book Value

Annual Sales
$77.80 million
Book Value
$0.95 per share

Miscellaneous

Free Float
78,078,000
Market Cap
$2.76 billion
Optionable
Optionable
Beta
0.57

Key Executives

  • Mr. Mark J. FoleyMr. Mark J. Foley (Age 58)
    CEO & Director
    Comp: $1.4M
  • Mr. Dustin S. Sjuts (Age 44)
    Pres
    Comp: $829.22k
  • Mr. Tobin C. SchilkeMr. Tobin C. Schilke (Age 48)
    CFO & Principal Accounting Officer
    Comp: $633.61k
  • Mr. Aubrey RankinMr. Aubrey Rankin (Age 47)
    Consultant
    Comp: $881.24k
  • Jessica Serra
    Head of Investor Relations & ESG
  • Mr. Dwight MoxieMr. Dwight Moxie (Age 46)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Jeanie D. Herbert
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Taryn Conway
    VP of Marketing
  • Mr. Justin Ford
    Sr. VP of HR & Head of People
  • Ms. Azita Nejad
    Sr. VP of Technical Operations













RVNC Stock - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price forecast for 2023?

7 brokerages have issued twelve-month price targets for Revance Therapeutics' stock. Their RVNC share price forecasts range from $24.00 to $65.00. On average, they predict the company's share price to reach $39.60 in the next year. This suggests a possible upside of 16.9% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2023?

Revance Therapeutics' stock was trading at $18.46 at the start of the year. Since then, RVNC stock has increased by 83.5% and is now trading at $33.88.
View the best growth stocks for 2023 here
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.32. The biopharmaceutical company earned $29.02 million during the quarter, compared to analysts' expectations of $28.76 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 461.54% and a negative net margin of 251.92%.

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.33%), Assenagon Asset Management S.A. (0.23%), Moody Aldrich Partners LLC (0.14%), Waypoint Capital Advisors LLC (0.07%), Inspire Investing LLC (0.02%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $33.88.

How much money does Revance Therapeutics make?

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $2.79 billion and generates $77.80 million in revenue each year. The biopharmaceutical company earns $-281,310,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Revance Therapeutics have?

The company employs 495 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.

This page (NASDAQ:RVNC) was last updated on 1/27/2023 by MarketBeat.com Staff